HealthWiredabout 1 hour ago
Synchron Pauses Brain Implant Trials
4 min read
Brain implant company Synchron pauses clinical trials for its second-generation Stentrode device due to performance issues involving the lead. The Brooklyn-based startup eliminates jobs and scales back its New York footprint while building a San Diego team to redesign the hardware. CEO Tom Oxley states the pause is a company decision, not FDA-directed, and enrollment resumes after upgrades.
Level
Hype check
Tap to vote and see what everyone thinks.